JPMorgan analyst Eric Joseph raised the firm’s price target on TG Therapeutics (TGTX) to $49 from $46 and keeps an Overweight rating on the shares. The firm updated the company’s model post earnings.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- TG Therapeutics reports Q3 EPS $2.43, consensus 22c
- TG Therapeutics raises FY25 revenue view $600M from $585M, consensus $588.12M
- TG Therapeutics completes enrollment in Phase 3 ENHANCE trial
- TGTX Earnings this Week: How Will it Perform?
- TG Therapeutics’ New Study on Ublituximab: A Potential Game-Changer for Pediatric MS Treatment